Literature DB >> 24063284

Enhancement of proliferation and invasion by MicroRNA-590-5p via targeting PBRM1 in clear cell renal carcinoma cells.

Xiangcheng Xiao1, Cene Tang, Shan Xiao, Chunyan Fu, Pingping Yu.   

Abstract

MicroRNAs (miRNAs) play an important role in cancer development. In our study, miR-590-5p is found to be upregulated in the examined renal cell carcinoma (RCC) cell lines. PBRM1 acts as tumor suppressor in RCC, and its downregulation is associated with increased proliferation and aggressive behavior in RCC. We confirmed that PBRM1 was a direct target of miR-590-5p. miR-590-5p could regulate PBRM1 mRNA and protein expressions in clear cell renal carcinoma (ccRCC) ACHN and 786-O cells. Downregulation of miR-590-5p, which resulted in increased PBRM1, inhibited proliferation and invasion of ccRCC cells. Upregulation of miR-590-5p, which resulted in decreased PBRM1, promoted proliferation and invasion of ccRCC cells. The process of miR-590-5p promoting proliferation was found to be implicated in its inhibition of G1/S transition of ccRCC cells, and the action mechanisms were involved in its downregulation of PBRM1/p21(WAF1/CIP1) expression. In conclusion, we identified the role of miR-590-5p, serving as an oncomir in ccRCC, and our findings provide a potential target for the treatment of ccRCC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24063284     DOI: 10.3727/096504013X13775486749335

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  38 in total

1.  miR-709 up-regulated in hepatocellular carcinoma, promotes proliferation and invasion by targeting GPC5.

Authors:  Tonggang Liu; Xuezhong Zhang; Kaihui Sha; Xianxian Liu; Liguo Zhang; Bangmao Wang
Journal:  Cell Prolif       Date:  2015-03-27       Impact factor: 6.831

2.  miR-421 is a diagnostic and prognostic marker in patients with osteosarcoma.

Authors:  Shuguang Zhou; Bing Wang; Jun Hu; Yucheng Zhou; Mengzhen Jiang; Mingyu Wu; Liming Qin; Xuming Yang
Journal:  Tumour Biol       Date:  2016-01-13

3.  Low PBRM1 identifies tumor progression and poor prognosis in breast cancer.

Authors:  Dan Mo; Chunhong Li; Junrong Liang; Qunfeng Shi; Naiwei Su; Shuyou Luo; Tian Zeng; Xinning Li
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

4.  MicroRNA-590-3p enhances the radioresistance in glioblastoma cells by targeting LRIG1.

Authors:  Long Chen; Wenhua Wang; Shengqiang Zhu; Xuegang Jin; Jian Wang; Jianfang Zhu; Youxin Zhou
Journal:  Exp Ther Med       Date:  2017-06-28       Impact factor: 2.447

5.  miR-506 inhibits the proliferation and invasion by targeting IGF2BP1 in glioblastoma.

Authors:  Yonggang Luo; Ranran Sun; Jun Zhang; Tongwen Sun; Xianzhi Liu; Bo Yang
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

Review 6.  MicroRNA expression and its clinical implications in Ewing's sarcoma.

Authors:  Zheng Li; Xin Yu; Jianxiong Shen; William Ka Kei Wu; Matthew T V Chan
Journal:  Cell Prolif       Date:  2014-12-22       Impact factor: 6.831

7.  MicroRNA-125a-5p inhibits invasion and metastasis of gastric cancer cells by targeting BRMS1 expression.

Authors:  Yi Cao; Shengxing Tan; Yi Tu; Guoyang Zhang; Yi Liu; Daojiang Li; Shan Xu; Zhibiao Le; Jianbo Xiong; Wenyu Zou; Peitao Gong; Zhengrong Li; Zhigang Jie
Journal:  Oncol Lett       Date:  2018-02-07       Impact factor: 2.967

Review 8.  PAQR3: a novel tumor suppressor gene.

Authors:  Xin Yu; Zheng Li; Matthew Tv Chan; William Ka Kei Wu
Journal:  Am J Cancer Res       Date:  2015-08-15       Impact factor: 6.166

9.  Downregulation of miR-30a is associated with proliferation and invasion via targeting MEF2D in cervical cancer.

Authors:  Jing Zhao; Bo Li; Chuqiang Shu; Yun Ma; Yingping Gong
Journal:  Oncol Lett       Date:  2017-10-02       Impact factor: 2.967

10.  Systematic identification of key genes and pathways in clear cell renal cell carcinoma on bioinformatics analysis.

Authors:  Zhao-Hui Tian; Cheng Yuan; Kang Yang; Xing-Liang Gao
Journal:  Ann Transl Med       Date:  2019-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.